nir

/nir

About nir

This author has not yet filled in any details.
So far nir has created 203 blog entries.

Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences

JERUSALEM, Feb. 7, 2017  /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 13-14, 2017 [...]

2018-05-30T17:04:04+00:00 Categories: Press Releases|Tags: |

Oramed to Present at the BIO CEO & Investor Conference

JERUSALEM, February 4, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 18th Annual BIO CEO & Investor Conference, taking place February 8-9, 2016 [...]

2018-05-30T17:04:15+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals’ Shareholder Letter

JERUSALEM, January 6, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), today issued the following shareholder letter: Dear Shareholders,  2015 was a very significant year for us at Oramed setting the bar high for what we anticipate to be a momentous year ahead in [...]

2018-05-30T17:04:16+00:00 Categories: Press Releases|Tags: |

Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China

JERUSALEM, December 29, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, today announced the closing of its previously-announced license and investment deal with Hefei Tianhui Incubation of Technologies Co. Ltd. ("HTIT"). Oramed has sold 1,155,367 restricted shares [...]

2018-05-30T17:04:16+00:00 Categories: Press Releases|Tags: |

Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China

Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share JERUSALEM, Nov. 30, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it [...]

2018-05-30T17:04:16+00:00 Categories: Press Releases|Tags: |

Oramed to Present at the Aegis Capital Growth Conference

JERUSALEM, October 1, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place October 7-9, 2015 in Las [...]

2018-05-30T17:04:16+00:00 Categories: Press Releases|Tags: |

Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study

180 Patients Expected to be Enrolled in Study JERUSALEM, September 9, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that 98 patients have already been enrolled in the Company's [...]

2018-05-30T17:04:17+00:00 Categories: Press Releases|Tags: |